KOD
KOD 50 articles

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

fool.com·3d ago

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

zacks.com·May 8

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

prnewswire.com·May 7

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

prnewswire.com·May 1

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

zacks.com·Apr 30

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

zacks.com·Apr 1

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

prnewswire.com·Mar 31

Kodiak Sciences: Road To $120

forbes.com·Mar 30

Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?

defenseworld.net·Mar 28

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

zacks.com·Mar 27

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

benzinga.com·Mar 27

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

reuters.com·Mar 26

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

prnewswire.com·Mar 26

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing

fool.com·Mar 9

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $28.29 Consensus Target Price from Brokerages

defenseworld.net·Mar 5

Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

fool.com·Feb 23

Kodiak Sciences (NASDAQ:KOD) Shares Down 5.9% – What’s Next?

defenseworld.net·Feb 22

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

fool.com·Feb 19

Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio

gurufocus.com·Feb 13

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

zacks.com·Feb 6

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

prnewswire.com·Feb 4

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $26.57 Average PT from Brokerages

defenseworld.net·Jan 14

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

seekingalpha.com·Jan 12

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

prnewswire.com·Jan 7

Kodiak Sciences (NASDAQ:KOD) Shares Down 5.8% – What’s Next?

defenseworld.net·Dec 28

Kodiak Sciences (NASDAQ:KOD) Hits New 12-Month High – Here’s What Happened

defenseworld.net·Dec 25

Kodiak Sciences (NASDAQ:KOD) Shares Gap Up Following Insider Buying Activity

defenseworld.net·Dec 23

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

zacks.com·Dec 22

Bros. Advisors Lp Baker Acquires 2,608,696 Shares of Kodiak Sciences (NASDAQ:KOD) Stock

defenseworld.net·Dec 21

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

prnewswire.com·Dec 18

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

prnewswire.com·Dec 16

Kodiak Sciences Announces Proposed Public Offering of Common Stock

prnewswire.com·Dec 15

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

zacks.com·Nov 14

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

prnewswire.com·Nov 13

Kodiak Sciences to Present at Upcoming Investor Conferences

prnewswire.com·Nov 12

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

prnewswire.com·Nov 5

The Big 3: GOOGL, KOD, FTK

youtube.com·Oct 31

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

prnewswire.com·Sep 15

Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report?

zacks.com·Sep 12

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

prnewswire.com·Sep 2

Harbour BioMed Reports 2025 Interim Results

prnewswire.com·Aug 27

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

benzinga.com·Aug 27

Kodiak Sciences to Present at American Chemical Society Fall 2025

prnewswire.com·Aug 19

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

zacks.com·Aug 14

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

prnewswire.com·Aug 13

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

prnewswire.com·Jul 10

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

prnewswire.com·Jun 25

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

zacks.com·Jun 13

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

prnewswire.com·May 29

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

zacks.com·May 15